Nanobodies with cross-neutralizing activity provide prominent therapeutic efficacy in mild and severe COVID-19 rodent models-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Nanobodies with cross-neutralizing activity provide prominent therapeutic efficacy in mild and severe COVID-19 rodent models

Published:2023-10 Issue:5 Volume:38 Page:787-800
ISSN:1995-820X
Container-title:Virologica Sinica
language:en
Short-container-title:Virologica Sinica

Author:

Han Qiuxue,Wang Shen,Wang Zhenshan,Zhang Cheng,Wang Xinyue,Feng Na,Wang Tiecheng,Zhao Yongkun,Chi Hang,Yan Feihu,Xia Xianzhu

Publisher

Elsevier BV

Subject

Virology,Molecular Medicine,Immunology,Infectious Diseases

Reference65 articles.

1. Effects of previous infection and vaccination on symptomatic omicron infections;Altarawneh;N. Engl. J. Med.,2022

2. Targeting neuroinvasion by SARS-CoV-2: emerging trends in drug and antibody delivery to combat covid-19;Baig;ACS Chem. Neurosci.,2021

3. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies;Barnes;Nature,2020

4. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies;Baum;Science,2020

5. Stat2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters;Boudewijns;Nat. Commun.,2020

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Three in one: An effective and universal vaccine expressing heterologous tandem RBD trimer by rabies virus vector protects mice against SARS-CoV-2;Antiviral Research;2024-07

2. Serial Llama Immunization with Various SARS-CoV-2 RBD Variants Induces Broad Spectrum Virus-Neutralizing Nanobodies;Vaccines;2024-01-26

3. SARS-CoV-2 Specific Nanobodies Neutralize Different Variants of Concern and Reduce Virus Load in the Brain of h-ACE2 Transgenic Mice;Viruses;2024-01-25

4. Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities;Current Topics in Microbiology and Immunology;2024

5. Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy;Human Vaccines & Immunotherapeutics;2023-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3